Microcap Ledger bioAffinity Technologies, Inc. $BIAF
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Services-Commercial Physical & Biological Research
- Headquarters
- San Antonio, TX
- Fiscal year end
- December 31
- Shares outstanding
- 8,101,725 [10-Q 2026-08-07]
What the company doesAI summary of filing
bioAffinity Technologies develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other lung diseases using flow cytometry and machine learning. Its first commercial product, CyPath® Lung, analyzes cell populations in sputum samples to identify cancer-related cells; the test is performed by the company's wholly owned subsidiary Precision Pathology Laboratory Services, a CAP-accredited and CLIA-certified clinical laboratory. The company generates revenue from CyPath® Lung testing and other pathology services, though it is discontinuing unprofitable pathology services to focus on lung cancer diagnostics. The company is currently revenue-generating, with CyPath® Lung testing revenue of $963,000 in 2025 (up 87% from 2024), and is also advancing companion diagnostic tests for asthma and COPD as well as cancer therapeutic research through its OncoSelect® Therapeutics subsidiary. [10-K 2026-03-16]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $2.86M | −$7.00M | −$6.43M | $2.43M | [10-Q 2026-08-07] |
| FY ended Dec 2025 | $6.16M | −$14.91M | −$9.33M | $6.45M | [10-K 2026-03-16] |
| FY ended Dec 2024 | $9.36M | −$9.04M | −$7.26M | $1.11M | [10-K 2026-03-16] |
- Quarterly cash burn
- −$3.21M
- Cash runway Estimate
- ~2.3 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-12 | 15,584,635 | [10-Q 2024-11-14] |
| 2025-03-31 | 18,255,824 | [10-K/A 2025-04-29] |
| 2025-05-13 | 27,249,462 | [10-Q 2025-05-15] |
| 2025-08-13 | 28,468,612 | [10-Q 2025-08-14] |
| 2025-11-11 | 4,498,709 | [10-Q 2025-11-14] |
| 2026-03-13 | 4,498,675 | [10-K 2026-03-16] |
| 2026-05-04 | 4,534,906 | [10-Q 2026-05-11] |
| 2026-08-03 | 8,101,725 | [10-Q 2026-08-07] |
- Shelf registration
- S-3 filed 2026-08-27; declared effective 2026-09-04 [S-3 2026-08-27]
Listing status
Current status: 4 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-07-31. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-07-31 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-07-31] |
| 2025-08-13 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-08-13] |
| 2025-05-30 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-05-30] |
| 2025-02-07 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-02-07] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-09 | 8-K | Material agreement entered; Unregistered sale of equity; Other events |
| 2026-10-09 | 424B5 | Prospectus or prospectus supplement |
| 2026-10-09 | 424B5 | Prospectus or prospectus supplement |
| 2026-10-08 | 8-K | Other events |
| 2026-10-06 | 8-K | Other events |
| 2026-09-30 | 8-K | Other events |
| 2026-09-29 | PRE 14A | Proxy statement |
| 2026-09-22 | 8-K | Other events |
| 2026-09-17 | 8-K | Other events |
| 2026-09-11 | 8-K | Regulation FD disclosure |
| 2026-09-09 | 8-K | Other events |
| 2026-09-08 | 424B3 | Prospectus or prospectus supplement |
Alerts for $BIAF
Email me when bioAffinity Technologies, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.